On July 6, 2023 REGiMMUNE Limited (REGiMMUNE), a biotech company focused on creating innovative immunotherapies for immune disorders and cancer, reported Hua Nan Securities as the lead underwriter for its upcoming initial public offering (IPO) in Taiwan (Press release, REGimmune, JUL 6, 2023, View Source [SID1234642232]). The IPO is anticipated to take place in 2025, signifying an important milestone in REGiMMUNE’s expansion and entry into the Taiwanese financial market.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
REGiMMUNE Limited’s core technology stems from Riken, a renowned national research institute based in Japan. Our main area of concentration revolves around pioneering immunotherapies that regulate regulatory T cells, also known as Tregs. In 2006, we were founded in Japan, and subsequently REGiMMUNE group has reorganized its Taiwanese entity, REGiMMUNE Limited, to become the holding company for the entire group, and now owns 100% of REGiMMUNE Corporation, its Japanese subsidiary, and REGiMMUNE Inc, its U.S. subsidiary. Our company’s fundamental philosophy, "From Care to Cure for Immune Disorders," highlights our commitment to not only the care of immune diseases but also their cure.
REGiMMUNE Limited provides innovative therapeutic solutions to patients with autoimmune diseases and cancer through its reVax technology platform and antibody drugs. The lead program, RGI-2001, has the potential to be a first-in-class small molecule drug for preventing acute graft-versus-host disease (aGvHD), a fatal complication of allogeneic hematopoietic stem cell transplantation that results in rejection, by enhancing current therapeutic approaches with a novel mechanism. RGI-2001 was selected for oral presentation at the American Society of Hematology (ASH) (Free ASH Whitepaper) annual meeting in December 2022 and is planned to be submitted to the FDA for Phase III IND and begin discussions on Fast Track Designation and Breakthrough Therapy Designation, which will be awarded to breakthrough drugs. In the final quarter of 2023, with clinical trials scheduled to commence in the third quarter of 2024.
In March 2023, a licensing agreement regarding RGI-2001 was signed between REGiMMUNE and SanFu Biotech, which is a subsidiary of SanFu Chemical Group. This agreement grants SanFu Biotech the exclusive rights to develop and commercialize RGI-2001 in Asia. SanFu Biotech is considered a valuable strategic partner by REGiMMUNE in the Asian market due to their extensive resources in the biotechnology and biomedical sectors, as well as its exceptional innovative strategies. REGiMMUNE is excited to collaborate with SanFu Biotech to accelerate the progress of RGI-2001 in this significant market.
Taiwan’s biomedical sector boasts a robust clinical trial infrastructure, favorable access to capital markets, extensive research and development capabilities, and a vast human biological database. With steadfast government backing, Taiwan has established itself as a leader in Asia’s biotechnology and medical sector. REGiMMUNE is committed to harnessing Japan’s proficiency in fundamental research and Taiwan’s complete industrial ecosystem in applied research and development to maximize the commercial potential of fundamental research and foster mutually beneficial business opportunities. We are thrilled to partner with Taiwan’s biotech industry to explore the global market and aspire to become the first Japanese novel drug research firm to be listed in Taiwan and embody Taiwan-Japan collaboration in the biotech field, with the support of the officers and colleagues at all levels in Hua Nan Securities.